As it turns out, they don't need the share authorization anyway in order to do the offering. The expanded authorization is for future purposes and I still would have supported it if you asked me yesterday, as I assumed it was a negotiating weapon in deal conversations with Big Pharma. Now I don't see a reason to vote in favor of it.